Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SciRhom

Request full access

Developing a new treatment for autoimmune diseases

Planegg, GermanyFounded 2016Biotech & Life Sciences

About SciRhom

Scirhom is a biotechnology company focused on developing innovative therapies targeting iRhom2, an inactive rhomboid protease. The company aims to address unmet medical needs in the fields of immunology, inflammation, oncology, infectious, and metabolic diseases. By inhibiting iRhom2, Scirhom seeks to selectively target the pro-inflammatory functions of TACE (Tumor Necrosis Factor-Alpha Converting Enzyme) without causing the severe side effects associated with direct TACE inhibition. This approach offers a promising alternative for treating conditions such as rheumatoid arthritis, hemophilia-induced inflammatory arthritis, and systemic lupus erythematosus. Scirhom's business model revolves around research and development, with a focus on preclinical and clinical trials to validate the efficacy and safety of their iRhom2 inhibitors. The company generates revenue through partnerships, licensing agreements, and potential future sales of approved therapies. Scirhom serves pharmaceutical companies, healthcare providers, and patients seeking advanced treatments for chronic inflammatory and autoimmune diseases.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
72.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Immune System, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jul 2024 $69M $277M HTGF · Wellington Partners · MIG Capital · Andera Partners ↗
SEEDOther financing Nov 2021 $8.8M $35M Undisclosed ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

SciRhom website traffic

Latest recorded traffic for SciRhom is 330 monthly website visits, down 5.7% over the last three months. SciRhom's team declined 5.3% over the past year.

Latest monthly visits330 3-month web change-5.7% 1-year team growth-5.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SciRhom in the Planegg ecosystem

Live from Dealroom

The SciRhom office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Wellington Partners
  • MIG Capital
  • Andera Partners
  • Hadean Ventures
  • Kurma Partners
  • HTGF
  • Bayern Kapital
  • PhiFund Ventures

Other known investors1 additional known investor

  • Innovation and Start-Up Center for Biotechnology (IZB)
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇩🇪 Germany61.5%
🇫🇷 France15.4%
🇸🇪 Sweden7.7%
🇺🇸 United States7.7%
🇳🇴 Norway7.7%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SciRhom on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SciRhom’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.